Interaction between the UCP2 -866 G>A polymorphism, diabetes, and β-blocker use among patients with acute coronary syndromes
Amber L. Beitelshees(University of Maryland, Baltimore), Daniel P. Kelly(Cardiovascular Institute of the South), Samuel Klein(Columbia University), Issam Zineh(United States Food and Drug Administration), Elisa Fabbrini(Sapienza University of Rome), Sharon Cresci(Washington University in St. Louis), Brian N. Finck(Washington University in St. Louis), Jun Wu(Sanford Burnham Prebys Medical Discovery Institute), Teresa C. Leone(Cardiovascular Institute of the South), Michael A. Province, Erik P. Kirk(Southern Illinois University Edwardsville), John A. Spertus(Saint Luke's Health System)
Cited by 17
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
|Circulation|2011|1.8k
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease
|Journal of Clinical Investigation|2006|1.4k
Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis
|Journal of Clinical Investigation|2000|1.3k